Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management

References

• MuraseESiegelmanESOutwaterEKPerez-JaffeLATureckRWUterine leiomyomas: histopathologic features, MR imaging findings, differential diagnosis, and treatmentRadiographics19991951179119710489175
   PubMed Web of Science ®Google Scholar
• WallachEEVlahosNFUterine myomas: an overview of development, clinical features, and managementObstet Gynecol2004104239340615292018
   PubMed Web of Science ®Google Scholar
• BukulmezODoodyKJClinical features of myomasObstet Gynecol Clin North Am2006331698416504807
   PubMed Web of Science ®Google Scholar
• OkoloSIncidence, aetiology and epidemiology of uterine fibroidsBest Pract Res Clin Obstet Gynaecol200822457158818534913
   PubMed Web of Science ®Google Scholar
• WegienkaGBairdDDHertz-PicciottoISelf-reported heavy bleeding associated with uterine leiomyomataObstet Gynecol2003101343143712636944
   PubMed Web of Science ®Google Scholar
• ZimmermannABernuitDGerlingerCSchaefersMGeppertKPrevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 womenBMC Womens Health201212622448610
   PubMed Web of Science ®Google Scholar
• SegarsJHParrottECNagelJDProceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendationsHum Reprod Update201420330933324401287
   PubMed Web of Science ®Google Scholar
• LefebvreGVilosGAllaireCThe management of uterine leiomyomasJ Obstet Gynaecol Can200325539641812738981
   PubMedGoogle Scholar
• NHS National Institute for Health and Clinical ExcellenceNICE Clinical Guideline 44: Heavy Menstrual BleedingLondon, UKNational Institute for Health and Clinical Excellence2007 Available from: http://www.nice.org.uk/guidance/cg44/resources/guidance-heavy-menstrual-bleeding-pdfAccessed April 23, 2013
   Google Scholar
• Chabbert-BuffetNEsberNBouchardPFibroid growth and medical options for treatmentFertil Steril2014102363063925171950
   PubMed Web of Science ®Google Scholar
• LethabyAVollenhovenBSowterMEfficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic reviewBJOG2002109101097110812387461
   PubMed Web of Science ®Google Scholar
• BatzerFRGnRH analogs: options for endometriosis-associated pain treatmentJ Minim Invasive Gynecol200613653954517097577
   PubMed Web of Science ®Google Scholar
• DonnezJTomaszewskiJVazquezFUlipristal acetate versus leuprolide acetate for uterine fibroidsN Engl J Med2012366542143222296076
   PubMed Web of Science ®Google Scholar
• EvansPBrunsellSUterine fibroid tumors: diagnosis and treatmentAm Fam Physician200775101503150817555142
   PubMed Web of Science ®Google Scholar
• BriggsAClaxtonKSculpherMDecision Modelling for Health Economic EvaluationNew York, NYOxford University Press2006
   Google Scholar
• Actavis CanadaFibristal Product MonographOakville, ONWatson Laboratories2013 Available from: http://www.actavis.ca/NR/rdonlyres/04E31D66-291E-4603-92AE-0933A77D9B64/0/Fibristal_Product_Monograph_English.pdfAccessed February 8, 2015
   Google Scholar
• HusereauDDrummondMPetrouSConsolidated Health Economic Evaluation Reporting Standards (CHEERS) statementInt J Technol Assess Health Care201329211712223587340
   PubMed Web of Science ®Google Scholar
• IstreOTrolleBTreatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resectionFertil Steril200176230430911476777
   PubMed Web of Science ®Google Scholar
• HuxMNgCLozano-OrtegaGFerrazziSGoereeRUtility values for premenopasal women suffering from symptomatic uterine fibroidsExpert Rev Pharmacoecon Outcomes Res201515118118925284595
   PubMed Web of Science ®Google Scholar
• HerdmanMGudexCLloydADevelopment and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Qual Life Res201120101727173621479777
   PubMed Web of Science ®Google Scholar
• Patented Medicine Prices Review Board [homepage on the Internet]Wholesale up-charge policies of Canada’s public drug planAppendix C: Drug Plan Summaries2012 Available from: http://www.pmprb-cepmb.gc.ca/english/view.asp?x=1591&mid=1495Accessed February 8, 2015
   Google Scholar
• Ontario Ministry of Health and Long-term Care [homepage on the Internet]Ontario Drug Benefit Program: Dispensing fees2012 Available from: http://www.health.gov.on.ca/en/public/programs/drugs/programs/odb/opdp_dispensing_fees.aspxAccessed February 8, 2015
   Google Scholar
• Ontario Ministry of Health and Long-term Care [homepage on the on the Internet]Drugs funded by Ontario Drug Benefit (ODB) Program e-Formulary2013 Available from: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspxAccessed February 8, 2015
   Google Scholar
• BriggsAHGoereeRBlackhouseGO’BrienBJProbabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux diseaseMed Decis Making200222429030812150595
   PubMed Web of Science ®Google Scholar
• RosatiPExacoustosCMancusoSLongitudinal evaluation of uterine myoma growth during pregnancy. A sonographic studyJ Ultrasound Med199211105115151404579
   PubMed Web of Science ®Google Scholar
• ViswanathanMHartmannKMcKoyNManagement of uterine fibroids: an update of the evidenceEvid Rep Technol Assess (Full Rep)2007154112218288885
   PubMedGoogle Scholar
• CoteIJacobsPCummingDWork loss associated with increased menstrual loss in the United StatesObstet Gynecol2002100468368712383534
   PubMed Web of Science ®Google Scholar
• DownesESikiricaVGilabert-EstellesJThe burden of uterine fibroids in five European countriesEur J Obstet Gynecol Reprod Biol201015219610220598796
   PubMed Web of Science ®Google Scholar
• HartmannKEBirnbaumHBen-HamadiRAnnual costs associated with diagnosis of uterine leiomyomataObstet Gynecol2006108493093717012456
   PubMed Web of Science ®Google Scholar
• LeeDWOzminkowskiRJCarlsGSThe direct and indirect cost burden of clinically significant and symptomatic uterine fibroidsJ Occup Environ Med200749549350617495692
   PubMed Web of Science ®Google Scholar
• Statistics Canada [homepage on the Internet]Average hourly wages of employees by selected characteristics and profession, unadjusted data, by province (monthly) (Canada)2013 Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr69a-eng.htmAccessed May 4, 2013
   Google Scholar
• PronGCohenMSoucieJThe Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on lifeFertil Steril200379111211912524073
   PubMed Web of Science ®Google Scholar
• LaupacisAFeenyDDetskyASTugwellPXHow attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluationsCMAJ199214644734811306034
   PubMed Web of Science ®Google Scholar
• NagyBTimarGJozwiak-HagymasyJThe cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroidsEur J Obstet Gynecol Reprod Biol2014175758124568866
   PubMed Web of Science ®Google Scholar
• DrummondMBarbieriMCookJTransferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportValue Health200912440941819900249
   PubMed Web of Science ®Google Scholar
• DonnezJTatarchukTFBouchardPUlipristal acetate versus placebo for fibroid treatment before surgeryN Engl J Med2012366540942022296075
   PubMed Web of Science ®Google Scholar
• WhiteheadSJAliSHealth outcomes in economic evaluation: the QALY and utilitiesBr Med Bull20109652121037243
   PubMed Web of Science ®Google Scholar